DHR Stock Analysis: Danaher | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 155.423m USD | 12M Return: 24.6% | US2358511028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 780M
EPS Trend: -44.8%
Qual. Beats: 2
Rev. Trend: -17.3%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Danaher Corporation (NYSE: DHR) is a U.S.-based diversified manufacturer and marketer of professional, medical, research, and industrial products and services, with operations primarily in the United States, China, and other international markets. The company is classified within the Health Care sector (Health Care Equipment sub-industry) and operates through three core segments: Biotechnology, Life Sciences, and Diagnostics.
The Biotechnology segment supplies technologies, consumables, and services that support the development and manufacturing of therapeutics, including cell culture media, chromatography resins, filtration products, aseptic fill-finish solutions, single-use manufacturing hardware, and lab-scale protein purification and analytical tools. This segment serves the bioprocessing and biopharmaceutical production value chain, where demand is driven by the growth of biologics, biosimilars, and advanced therapy manufacturing.
The Life Sciences segment offers instruments and consumables such as mass spectrometers, flow cytometry systems, lab automation, centrifugation, microscopes, and genomic medicine products, marketed under well-known brands including Beckman Coulter, Leica Microsystems, Pall, Phenomenex, SCIEX, Abcam, Aldevron, IDT, and Molecular Devices. The portfolio reflects Danahers brand-ownership business model, in which it acquires and operates specialized life science brands serving research, academic, and pharmaceutical customers.
The Diagnostics segment provides clinical instruments, consumables, software, and services used by hospitals, physicians offices, reference laboratories, and critical care settings to diagnose disease and guide treatment decisions. This segment benefits from recurring revenue tied to installed instrument bases and ongoing consumable usage.
The company was incorporated in 1969 under the name Diversified Mortgage Investors, Inc. and was renamed Danaher Corporation in 1984. It is headquartered in Washington, D.C., and trades on the NYSE under the ticker DHR with a large-cap market capitalization.
- Bioprocessing order growth drives Biotechnology segment expansion
- Abcam acquisition expands protein research consumables revenue base
- China revenue softness and FX weigh on reported growth
| Net Income: 4.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.04 > 1.0 |
| NWC/Revenue: 21.01% < 20% (prev 17.52%; Δ 3.49% < -1%) |
| CFO/TA 0.07 > 3% & CFO 6.63b > Net Income 4.00b |
| Net Debt (23.5b) to EBITDA (7.15b): 3.28 < 3 |
| Current Ratio: 1.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (707.6m) vs 12m ago -1.60% < -2% |
| Gross Margin: 58.51% > 18% (prev 61.45%; Δ -2.94% > 0.5%) |
| Asset Turnover: 28.86% > 50% (prev 29.42%; Δ -0.56% > 0%) |
| Interest Coverage Ratio: 17.31 > 6 (EBIT TTM 5.05b / Interest Expense TTM 292.0m) |
| A: 0.06 (Total Current Assets 13.4b - Total Current Liabilities 8.11b) / Total Assets 92.4b |
| B: 0.52 (Retained Earnings 48.2b / Total Assets 92.4b) |
| C: 0.06 (EBIT TTM 5.05b / Avg Total Assets 87.0b) |
| D: 1.32 (Book Value of Equity 52.6b / Total Liabilities 39.8b) |
| Altman-Z'' = 3.85 = AA |
| DSRI: 0.84 (Receivables 3.96b/4.52b, Revenue 25.1b/24.0b) |
| GMI: 1.05 (GM 61.45% / 58.51%) |
| AQI: 0.99 (AQ_t 0.78 / AQ_t-1 0.79) |
| SGI: 1.05 (Revenue 25.1b / 24.0b) |
| TATA: -0.03 (NI 4.00b - CFO 6.63b) / TA 92.4b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at USD 224.49 with a total of 4,417,962 shares traded. Over the past week, the price has changed by +5.99%, over one month by +3.94%, over three months by +16.43% and over the past year by +24.63%.
Current recommended Stop Loss: 217.00 (which is 3.3% or 1.3 ATR below the current price).
Danaher has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy DHR.
- StrongBuy: 18
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 230.8 | 2.8% |
P/E Trailing = 38.4504
P/E Forward = 23.2558
P/S = 6.1904
P/B = 2.8857
P/EG = 1.2921
Revenue TTM = 25.1b USD
EBIT TTM = 5.05b USD
EBITDA TTM = 7.15b USD
Long Term Debt = 25.1b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 27.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.28b
Net Debt = 23.5b USD (calculated: Debt 27.8b - CCE 4.35b)
Enterprise Value = 179b USD (155b + Debt 27.8b - CCE 4.35b)
Interest Coverage Ratio = 17.31 (Ebit TTM 5.05b / Interest Expense TTM 292.0m)
EV/FCF = 32.73x (Enterprise Value 179b / FCF TTM 5.47b)
FCF Yield = 3.06% (FCF TTM 5.47b / Enterprise Value 179b)
FCF Margin = 21.77% (FCF TTM 5.47b / Revenue TTM 25.1b)
Net Margin = 15.95% (Net Income TTM 4.00b / Revenue TTM 25.1b)
Gross Margin = 58.51% ((Revenue TTM 25.1b - Cost of Revenue TTM 10.4b) / Revenue TTM)
Gross Margin QoQ = 57.64% (prev 60.34%)
Tobins Q-Ratio = 1.94 (Enterprise Value 179b / Total Assets 92.4b)
Interest Expense / Debt = 1.05% (Interest Expense 292.0m / Debt 27.8b)
Taxrate = 15.92% (758.0m / 4.76b)
NOPAT = 4.25b (EBIT 5.05b * (1 - 15.92%))
Current Ratio = 1.65 (Total Current Assets 13.4b / Total Current Liabilities 8.11b)
Debt / Equity = 0.53 (Debt 27.8b / totalStockholderEquity, last quarter 52.6b)
Debt / EBITDA = 3.28 (Net Debt 23.5b / EBITDA 7.15b)
Debt / FCF = 4.30 (Net Debt 23.5b / FCF TTM 5.47b)
Total Stockholder Equity = 52.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.60% (Net Income 4.00b / Total Assets 92.4b)
RoE = 7.66% (Net Income TTM 4.00b / Total Stockholder Equity 52.3b)
RoCE = 6.53% (EBIT 5.05b / Capital Employed (Equity 52.3b + L.T.Debt 25.1b))
RoIC = 5.03% (NOPAT 4.25b / Invested Capital 84.4b)
WACC = 6.39% (E(155b)/V(183b) * Re(7.38%) + D(27.8b)/V(183b) * Rd(1.05%) * (1-Tc(0.16)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.19 | Cagr: -2.47%
[DCF] Terminal Value 76.93% ; FCFF base≈5.22b ; Y1≈5.78b ; Y5≈7.45b
[DCF] Fair Price = 128.2 (EV 114b - Net Debt 23.5b = Equity 90.1b / Shares 703.0m; r=8.35% [WACC [floored]]; 5y FCF grow 12.42% → 2.50% )
EPS Correlation: -44.84 | EPS CAGR: -3.20% | SUE: 1.24 | # QB: 2
Revenue Correlation: -17.26 | Revenue CAGR: -0.55% | SUE: 1.52 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.91 | Chg30d=-0.20% | Revisions=-50% | Analysts=21
EPS current Year (2026-12-31): EPS=8.51 | Chg30d=-0.02% | Revisions=+0% | GrowthEPS=+9.1% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=9.30 | Chg30d=+0.01% | Revisions=-18% | GrowthEPS=+9.3% | GrowthRev=+8.1%
[Analyst] Revisions Ratio: -25% (up=6, down=11)